8-K: KORU Medical Systems Reports Record Q2 Revenue Growth of 22% and Raises Full Year Guidance

KORU Medical Systems announced a record second quarter with 22% revenue growth and raised its full-year 2024 revenue and gross margin guidance.

Summary

• KORU Medical Systems reported a strong second quarter of 2024, achieving record revenues of $8.4 million, a 22% increase compared to the same period last year.
• The company's core business, encompassing both U.S. and international operations, grew by 20% year-over-year.
• Gross profit reached $5.5 million, a 41% increase from the prior year, with a gross margin of 65%, reflecting an 890 basis point improvement.
• The company's cash balance at the end of the quarter was $10.5 million, with a quarterly cash usage of $0.3 million.
• KORU Medical has raised its full-year 2024 revenue guidance to $32.0-$32.5 million, representing a 12-14% growth, and increased its full-year gross margin guidance to 61-62%.
• The company received regulatory clearance for its FreedomEdge Infusion System in Japan and is progressing its novel therapies pipeline, including a Phase III clinical trial for an expanded nephrology indication expected to launch in 2026.

Sentiment

Score: 8

Explanation: The document conveys a strong positive sentiment due to the record revenue growth, improved gross margins, raised guidance, and progress in novel therapies. While there is a net loss, the trend is positive, and the company is on track to achieve cash flow breakeven.

Positives

• The company experienced a significant 22% increase in revenue compared to the same quarter last year.
• Gross profit increased by 41% year-over-year, indicating improved profitability.
• The company's gross margin improved significantly by 890 basis points to 65%.
• KORU Medical is making progress in its novel therapies pipeline, with a clear path to commercial launches.
• The company is expanding its international presence and increasing market penetration.
• The company is raising its full year revenue and gross margin guidance.
• The company is on track to achieve cash flow breakeven in the fourth quarter of 2024 and be cash flow positive for the full year 2025.

Negatives

• The company reported a net loss of $1.0 million for the quarter, although this is an improvement from the $2.5 million loss in the same period last year.
• Adjusted EBITDA for the quarter was negative at ($0.4) million, although this is an improvement from the ($2.3) million in the same period last year.
• The company had a negative cash usage of $0.3 million for the quarter.

Risks

• The company's future performance is subject to uncertainties associated with SCIg market growth, prefilled syringe penetration, and plasma supply.
• Clinical trial activity and success, as well as the approval and commercialization of new drug indications, pose potential risks.
• The company faces risks related to its EU certification, the shift to increased healthcare delivery in the home, and new patient diagnoses.
• Global health crises, innovation and competition, labor and supply price increases, inflationary impacts, and labor supply could impact future results.

Future Outlook

KORU Medical has raised its full-year 2024 revenue guidance to $32.0-$32.5 million, representing a 12-14% growth, and increased its full-year gross margin guidance to 61-62%. The company also expects to achieve cash flow breakeven in the fourth quarter of 2024 and be cash flow positive for the full year 2025.

Management Comments

• Linda Tharby, KORU Medical's President and CEO, stated that the company delivered a great quarter, highlighted by strong double-digit growth, progress in their novel therapies pipeline, and increased operating leverage.
• She also mentioned that the US core business continues to capture share gains in a growing SCIg market and that the company is increasing penetration and expanding in new geographies internationally.
• She expressed pride in the KORU team and confidence in continued execution moving forward, leading to the raised full-year 2024 revenue and gross margin guidance.

Industry Context

The announcement reflects a positive trend in the medical technology sector, particularly in the area of subcutaneous infusion solutions. KORU Medical's growth is driven by the increasing demand for home healthcare and the expansion of the SCIg market. The company's focus on novel therapies and strategic collaborations positions it well for future growth in this competitive landscape.

Comparison to Industry Standards

• KORU Medical's 22% revenue growth in Q2 2024 is strong compared to the broader medical device industry, which typically sees single-digit growth rates.
• Companies like Insulet (PODD) and Tandem Diabetes Care (TNDM) in the diabetes space, which also use infusion technology, have seen similar growth rates in some quarters, but KORU's focus on subcutaneous infusion for other therapies provides a unique market position.
• The 65% gross margin is also impressive, indicating efficient operations and pricing power, and is comparable to other medical device companies with strong product portfolios.
• The company's progress in novel therapies and collaborations with companies like SCHOTT Pharma is similar to strategies employed by other medical device companies to expand their market reach and product offerings.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and raised guidance.
• Employees may be motivated by the company's success and future growth prospects.
• Customers will benefit from the company's innovative infusion solutions.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a lower risk due to its improved financial performance.

Next Steps

• The company will continue to progress its novel therapies pipeline, including the Phase III clinical trial for an expanded nephrology indication.
• KORU Medical will focus on expanding its market presence both domestically and internationally.
• The company will continue to execute on its strategic collaborations to drive market expansion and optimize drug delivery.
• The company will host a conference call and webcast to discuss these results and provide a corporate update.

Key Dates

Keywords

KORU Medical, Infusion Systems, Subcutaneous Infusion, Medical Technology, Revenue Growth, Gross Margin, Adjusted EBITDA, Clinical Trials, Regulatory Clearance, SCIg